Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10891350 | 0.81 | LPAR3 (0.61) | S1PR1S1PR3S1PR4S1PR2LPAR3 | |
| SCHEMBL23322415 | 0.76 | S1PR1 (0.44) | S1PR1S1PR3S1PR4S1PR2LPAR3 | |
| SCHEMBL10896043 | 0.76 | L3MBTL1 (0.54) | S1PR1S1PR3S1PR4S1PR2LPAR3 | |
| SCHEMBL30026758 | 0.75 | CA2 (0.65) | PSIP1CA2SMN1; SMN2GAA | |
| SCHEMBL759323 | 0.75 | LMNA (0.53) | LPAR1 | |
| SCHEMBL10179705 | 0.75 | CA2 (0.69) | PSIP1CA2SMN1; SMN2GAA | |
| SCHEMBL96074 | 0.74 | CA2 (0.66) | PSIP1CA2SMN1; SMN2GAA | |
| SCHEMBL28362924 | 0.73 | ALDH1A1 (0.54) | S1PR1S1PR3S1PR4S1PR2LPAR1 | |
| SCHEMBL10896156 | 0.72 | THRA (0.52) | S1PR1S1PR3S1PR4S1PR2LPAR3 | |
| SCHEMBL10791731 | 0.72 | ALDH1A1 (0.41) | CA2SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | PSIP1 1856/4885S1PR1 570/4885S1PR3 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.